CompletedNCT00550407
Lamotrigine or placebo to prevent mood episodes in bipolarity type I
About this title
An Evaluation Of BW430C (Lamotrigine) Versus Placebo In The Prevention Of Mood Episodes In Bipolar I Disorder Patients
Read the official source — NCT00550407Medication studyAges 20+Japan
Understand this study
Who was this study for?
Listed age limits: from 20 years.
- Listed locations
- Aichi and 59 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNovember 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 215
- Sponsor
- GlaxoSmithKline
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Japan
- Age range
- Over 20 Years
- Official registry ID
- NCT00550407
- Official title
Show the full official title
Study SCA104779, an Evaluation of BW430C (Lamotrigine) Versus Placebo in the Prevention of Mood Episodes in Bipolar I Disorder Patients
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedAichi · Chiba · Fukuoka
17 more locations
- Gunma
- Hiroshima
- Hokkaido
- Ibaraki
- Kanagawa
- Kumamoto
- Kyoto
- Mie
- Nara
- Okayama
- Osaka
- Ōita
- Saga
- Saitama
- Tokyo
- Tottori
- Yamagata
Questions about this study
Who is behind this study?
The study sponsor is GlaxoSmithKline.
Did this study involve medication?
Yes. The study involved medication, including lamotrigine and Placebo.
Who was this study for?
Listed age limits: from 20 years.
